FDA's stand on Provenge riles cancer patients

The FDA's decision to demand more data on Dendreon's cancer drug Provenge--after an advisory committee had recommended approval--has energized a host of prostate cancer patients. Advocacy groups have been raising their voices to protest--and in some cases make death threats--over what they see as a last hope for late-stage prostate cancer. Doctors have joined their voices to the chorus and some lawmakers have called for a probe of the decision. Regulators say there's no proof that it works. Patients say it's their only hope to add a couple of months to their lives.

- read the article from the Los Angeles Times

Suggested Articles

Halozyme CEO Helen Torley discusses how the company stayed alive after its lead program, a treatment for pancreatic cancer, failed in phase 3.

The under-active genes that cause heart problems and poor muscle movement in Down syndrome may also impede the growth of solid tumors, a study found.

The new funding will bankroll Dyne's preclinical programs in three muscle-wasting diseases, as well as discovery-stage work.